Cortice Biosciences, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Cortice Biosciences, Inc.
Among other Asia deals, Takeda adds to pair of recent gene therapy tie-ups with a CNS-focused cell therapy partnership with Immusoft; earlier it licensed ex-US rights to JCR’s Hunter syndrome drug.
Emerging Company Profile: Armed with fresh funds, French spin-out PEP-Therapy will begin a clinical proof of concept study assessing its lead therapeutic peptide as a potential treatment for metastatic triple-negative breast cancer and platinum-resistant ovarian cancer.
The family-owned German pharma dates back to 1885 and tries to keep up with its publicly traded peers by not mimicking everything they do, but with a “value by innovation” focus.
Only 25 more initial public offerings are needed for 2021 to beat 2020’s record-breaking 86 IPOs. However, the average return for this year’s offerings is just 1.1% as of 1 July versus 11% at the end of the first quarter.
- Other Names / Subsidiaries
- Archer Biosciences, Inc.